Navigation Links
Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement
Date:8/10/2009

    NASDAQ: CRME   TSX: COM

VANCOUVER and DEERFIELD, IL, Aug. 10 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

The decision to conduct another trial was reached following extended discussions with the FDA to define the best regulatory path forward for KYNAPID. Under the Special Protocol Assessment (SPA) process, the FDA has agreed that the design and planned analysis of the study adequately address objectives in support of the KYNAPID New Drug Application (NDA). The prospectively-defined trial will enroll recent-onset atrial fibrillation patients without a history of heart failure. Cardiome and Astellas believe that this study, coupled with the overall clinical development program, should in principle meet the FDA standards for approval.

"In addition to receiving a positive recommendation for approval from the FDA Cardiovascular and Renal Drugs Advisory Committee, KYNAPID has demonstrated consistent results across all of the four completed Phase 3 clinical trials," said William E. Fitzsimmons, PharmD, Senior Vice President, Development at Astellas. "We are confident that the ACT 5 trial will confirm these prior results and further demonstrate the therapeutic value of this exciting drug candidate."

"We support the decision to conduct the ACT 5 trial, and we will assist our partner Astellas in every way to expedite the launch and successful completion of this study," said Doug Janzen, President and Chief Executive Officer of Cardiome. "We estimate that Cardiome's alloca
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. aTyr Pharma Raises an Additional $12 Million
2. Texas Kidney Community: CMS Authorization to Survey 22 New Dialysis Centers Excellent First Step Toward Opening Additional Pending Facilities, Creating More Local Jobs
3. SETO Holdings, Inc. Enters Into Two Additional Leases for Two New Hearing Centers in Maryland and Virginia
4. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
5. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
6. Specialty Hospitals of Washington Adds Additional Skilled Nursing Facility Beds at United Medical Center in South East DC
7. King Provides Additional Information on the REMOXY(R) NDA Resubmission Plan
8. Visit to the doctor: The supply of additional private services is increasing
9. Business, Health Care Leaders Call on Texas Employers to Cover Smoking Cessation Benefits for an Additional 100,000 People by 2010
10. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
11. New Jersey University Hospital to Pay Additional $2 Million to Resolve Fraud Claims That Facility Double Billed Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The "North American Interventional ... by Angioplasty Balloon (Plain/Old, Cutting), Stent ... Filter (Retrievable), Endovascular Stent Graft - ... the major market drivers, restraints, and ... , Browse 108 market data tables ...
(Date:8/21/2014)... Rebecca Tabbert, owner of Calimesa Fit Body ... enjoyed watching as more people turn away from the ... camp environment. It’s not only good for her business; ... ‘treadmill-dumbbells-elliptical’ routine just doesn’t work,” she says. “Numerous research ... and lifting those cute little dumbbells does very little ...
(Date:8/21/2014)... Bedros Keuilian’s Annual Fitness Business Summit is considered ... many people already earning seven-figure incomes. But his annual ... open to the owners of Keuilian’s own international fitness boot ... Body Boot Camp World Conference will also be attended by ... camp or are struggling with their own boot camp ...
(Date:8/21/2014)... Chicago, IL (PRWEB) August 21, 2014 ... EB-5 Business & Investment Exploratory Delegation to southern China ... unique opportunity to explore the rapid growing cities of ... each delegate will have the rare opportunity to meet ... their project(s) during a short weeklong time frame. ...
(Date:8/21/2014)... August 21, 2014 mynt welcomes industry ... promoters to join its growing company. Since its pre-launch ... in product sales and continues to gain momentum leading ... , Rob and Tiffanie came into network marketing by ... a number of network marketing companies. Tiffanie needed help ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Calimesa Fit Body Boot Camp Announces Its Release of a New Video about the Fitness Boot Camp Experience 2Health News:Calimesa Fit Body Boot Camp Announces Its Release of a New Video about the Fitness Boot Camp Experience 3Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Artisan Business Group announces 2014 EB-5 Investment Trade Mission to China 2Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
... (HealthDay News) -- A combination of animal and human research ... could ultimately help in the treatment of major depression, researchers ... a brain protein known as p11. The study authors cite ... of reward, pleasure and satisfaction with positive life experiences. ...
... its Construction Unit, is participating in and coordinating a ... aim is to develop pest control products with lower ... and less damaging for human health. The two years ... Swedish University of Agricultural Sciences (SLU) and five SME ...
... car increases global temperatures in the long run more ... to a new study. However, in the short run ... because airplanes strongly affect short-lived warming processes at high ... & Technology , a semi-weekly journal. In the ...
... , TUESDAY, Oct. 19 (HealthDay News) -- A small group ... stop taking the cancer drug Gleevec (imatinib) have remained cancer-free ... online Oct. 19 in The Lancet Oncology , is ... go beyond long-term cancer control and offer some patients a ...
... Atlanta, GA, 20 October, 2010 Elsevier / MC ... than 1,300 healthcare organizations, has partnered with the Association ... module for Mosby,s Nursing Skills: Perioperative Collection, the only ... to be consistent with the Standards and Recommended ...
... , WEDNESDAY, Oct. 20 (HealthDay News) -- People with the ... serious eye damage, says a small new study from Greece. ... located near the center of the retina at the back ... vision and the processing of light. In this study, ...
Cached Medicine News:Health News:Animal Study Explores Potential Gene Therapy for Depression 2Health News:Animal Study Explores Potential Gene Therapy for Depression 3Health News:Tecnalia develops environment-friendly and health-friendly pest control products 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 3Health News:Elsevier/MC Strategies and AORN launch perioperative nursing skills collection 2Health News:People With Anorexia May Risk Serious Eye Damage 2
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... , Aug. 21, 2014  The board of ... a leading provider of clinical trial imaging solutions, today ... named chief financial officer, effective immediately.  Mr. Groff has ... August 2013.  He joined VirtualScopics in January 2006 as ... February 2013. "When the board of VirtualScopics ...
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST) and Chelsea Therapeutics ... micro-dosing trial of an,I-3D compound. , The ... the pharmacokinetic,characteristics of the compound in humans. ... The study demonstrated that the selected I-3D ...
... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... data from the Ranolazine Open Label,Experience (ROLE) program, ... to be safe and well,tolerated in patients with ... 3 clinical trials, and enrolled in the ROLE,program. ...
Cached Medicine Technology:Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
... offers improved ergonomics for today's exacting ... grippy finger rest and the large ... efficiency. Finnpipette Digitals also feature soft-touch ... (pat. pend.) and super blow-out for ...
... AlphaPette Pipettor is the #1 Pipettor ... accuracy, comfort, and reliability. Continuously adjustable. ... readout sub-micrometer. Easy interchangeable ejector buttons ... hands. Adjustable rapid pipet tip ejector ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
Research Series 2100 Adjustable-volume Pipette, 10-100 l, single-channel with adjustable-volume setting...
Medicine Products: